Form 4: 4D Molecular Therapeutics Chief Legal Officer Executes Stock Option Plan

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 18, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, executed transactions involving the company's common stock.
• Bizily exercised stock options to acquire 500 shares at $6.49 and 1,250 shares at $8.04.
• He then sold 1,750 shares at $31.27.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on October 10, 2023.
• Following these transactions, Bizily directly owns 1,737 shares of common stock, 16,043 stock options exercisable at $6.49, and 43,334 stock options exercisable at $8.04.

Sentiment

Score: 6

Explanation: The document is neutral in tone. It simply reports insider trading activity under a pre-arranged plan. There's no indication of positive or negative sentiment, just factual reporting.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have stock option plans and to periodically exercise those options and sell shares, especially under pre-arranged trading plans. The fact that the transactions were made under a 10b5-1 plan suggests that they were planned well in advance and not based on any inside information.

Comparison to Industry Standards

• Stock option grants and 10b5-1 trading plans are standard compensation practices for executives in publicly traded companies, including those in the biotechnology sector like 4D Molecular Therapeutics.
• Comparable companies such as BioMarin Pharmaceutical, Sarepta Therapeutics, and CRISPR Therapeutics also utilize stock options as part of their executive compensation packages.
• The vesting schedules and exercise prices of these options are generally in line with industry norms, designed to incentivize long-term performance and align executive interests with shareholder value.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an insider, but the impact is likely minimal given the relatively small number of shares involved and the fact that the transactions were pre-planned.

Key Dates